Nexoplex bio Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
231
- Latest Deal Type
-
Bankr. Admin/Reorg
Nexoplex bio General Information
Description
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.
Contact Information
Website
www.nexoplexbio.comCorporate Office
- 5959 Horton Street
- Suite 300
- Emeryville, CA 94608
- United States
Corporate Office
- 5959 Horton Street
- Suite 300
- Emeryville, CA 94608
- United States
Nexoplex bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Bankruptcy: Admin/Reorg | 10-Oct-2024 | Completed | Bankruptcy: Admin/Reorg | |||
| 10. 2PO | 02-Apr-2024 | Completed | Generating Revenue | |||
| 9. PIPE | 24-Oct-2022 | Completed | Generating Revenue | |||
| 8. Debt - General | 25-Feb-2022 | Completed | Generating Revenue | |||
| 7. PIPE | 17-Sep-2021 | Completed | Generating Revenue | |||
| 6. PIPE | 28-Dec-2020 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 4. IPO | 28-Sep-2018 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 29-Jun-2018 | $31M | $226M | Completed | Generating Revenue | |
| 2. Early Stage VC (Series B) | 07-Sep-2017 | $92.7M | $195M | Completed | Startup |
Nexoplex bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 61,260,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 34.98% |
Nexoplex bio Comparisons
Industry
Financing
Details
Nexoplex bio Competitors (48)
One of Nexoplex bio’s 48 competitors is ImmunityBio, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Lava Therapeutics | Formerly VC-backed | Utrecht, Netherlands | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
Nexoplex bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nexoplex bio Patents
Nexoplex bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026030253-A1 | Human papillomavirus (hpv) vaccines | Pending | 29-Jul-2024 | ||
| WO-2025199501-A1 | Human papillomavirus (hpv) vaccines | Pending | 22-Mar-2024 | ||
| WO-2024192143-A1 | Epitope prediction via a learned genotype network across class ii mhc alleles | Inactive | 13-Mar-2023 | ||
| WO-2024119048-A1 | Compositions and methods of use thereof | Inactive | 02-Dec-2022 | ||
| WO-2024097257-A1 | Combination panel cell-free dna monitoring | Inactive | 31-Oct-2022 | C12Q1/6874 |
Nexoplex bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nexoplex bio ESG
Risk Overview
Risk Rating
Updated January, 31, 2024
36.48 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,744
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Pharmaceuticals
Subindustry
of 423
Rank
Percentile
Nexoplex bio FAQs
-
When was Nexoplex bio founded?
Nexoplex bio was founded in 2015.
-
Where is Nexoplex bio headquartered?
Nexoplex bio is headquartered in Emeryville, CA.
-
What is the size of Nexoplex bio?
Nexoplex bio has 231 total employees.
-
What industry is Nexoplex bio in?
Nexoplex bio’s primary industry is Drug Discovery.
-
Is Nexoplex bio a private or public company?
Nexoplex bio is a Private company.
-
What is Nexoplex bio’s current revenue?
The current revenue for Nexoplex bio is .
-
How much funding has Nexoplex bio raised over time?
Nexoplex bio has raised $643M.
-
Who are Nexoplex bio’s competitors?
ImmunityBio, Aura Biosciences, Lava Therapeutics, Immunocore Holdings, and Sorrento Therapeutics are some of the 48 competitors of Nexoplex bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
